Get the Stockscreener App
17.02
0.41%
0.05
Definium Therapeutics Inc stock is traded at $17.02, with a volume of 867.01K.
It is up +0.41% in the last 24 hours and up +0.00% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
See More
Previous Close:
$16.97
Open:
$17.31
24h Volume:
867.01K
Relative Volume:
5.52
Market Cap:
$1.68B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.69
$17.45
1-Week Range:
$14.62
$18.12
52-Week Range:
$14.62
$18.12
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
17.02 | 1.67B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium launches educational campaign on LSD for mental health - Investing.com
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com Nigeria
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns - Yahoo Finance
Deinium Therapeutics (DFTX) Is Up 8.7% After Rebrand And DT120 Anxiety Pipeline UpdateWhat's Changed - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 1-Year 110% Surge? - Yahoo Finance
DFTX (Definium Therapeutics) Momentum Rank : 10 (As of Jan. 18, 2026) - GuruFocus
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress - Sahm
Definium Therapeutics stock hits 52-week high at 15.3 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 15.3 USD - Investing.com
Five new option listings and one option delisting on January 15th - TipRanks
MNMD: DT120 targets rapid, lasting relief for anxiety and depression, with pivotal data due in 2024 - TradingView — Track All Markets
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026 - Yahoo Finance
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 5.6%Here's What Happened - MarketBeat
Definium Therapeutics Rebrands and Highlights 2026 Pipeline - TipRanks
Definium Therapeutics (MNMD) Announces Rebranding and Ticker Cha - GuruFocus
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $339,151.65 in Stock - MarketBeat
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
MindMed Announces New Employee Inducement Grant - Business Wire
MindMed Reports Q3 2025 Financial Results and Business Updates - Business Wire
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
MindMed to Report Q3 2025 Financial Results on November 6, 2025 - Business Wire
Mind Medicine says it announces pricing of $225 million public offering at $12.25 per share - marketscreener.com
Mind Medicine Nears Pivotal Year: Strong Fundamentals Make It A Buy (NASDAQ:MNMD) - Seeking Alpha
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - The Motley Fool
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine Inc.(NasdaqGS: MNMD) added to Russell 3000 Value Index - marketscreener.com
MindMed to Participate in June Investor Conferences - marketscreener.com
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer - marketscreener.com
MindMed Announces New Employee Inducement Grants - marketscreener.com
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference - marketscreener.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - marketscreener.com
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - marketscreener.com
MindMed Appoints Matt Wiley as Chief Commercial Officer - marketscreener.com
MindMed to Present at Leerink's Global Healthcare Conference 2025 - marketscreener.com
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - marketscreener.com
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call (MNMD) - Seeking Alpha
MindMed to Be Added to the Nasdaq Biotechnology Index - marketscreener.com
Definium Therapeutics Inc Stock (DFTX) Financials Data
There is no financial data for Definium Therapeutics Inc (DFTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):